The Exchange has sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned CDSCO Flags 70 Drug Batches, Including Telma 40 And Eye Ointments, For Failing Quality Standards In March 2025 Tests. The response from the Company is attached.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Midcap 150 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE sought clarification from Glenmark Pharmaceuticals following a news report that the Central Drugs Standard Control Organisation (CDSCO) flagged 70 drug batches, including Telma 40 and certain eye ointments, for failing quality standards in March 2025 tests. The company has submitted its response to the exchange, which is attached to the filing. The matter relates to drug manufacturing quality compliance rather than a securities or financial market issue. Investors will need to review the company's response for details on the affected batches and any remedial actions taken.
This is a regulatory quality concern that could hurt brand reputation and potentially affect sales of the flagged products, but it does not appear to involve SEBI action, insolvency, or litigation. Short-term sentiment may be negative pending clarity on the scale and resolution.